Dyadic International Inc. (NASDAQ:DYAI) Short Interest Down 30.7% in March

Dyadic International Inc. (NASDAQ:DYAI) was the target of a significant drop in short interest during the month of March. As of March 13th, there was short interest totaling 65,770 shares, a drop of 30.7% from the February 26th total of 94,848 shares. Based on an average trading volume of 99,432 shares, the short-interest ratio is currently 0.7 days. Approximately 0.3% of the company’s shares are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $3.00.

Institutional Investors Weigh In On Dyadic International

Hedge funds and other institutional investors have recently modified their holdings of the company. Marathon Capital Management acquired a new position in shares of Dyadic International during the third quarter worth $41,000. Bank of America Corp DE raised its stake in Dyadic International by 16,146.7% in the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 26,965 shares in the last quarter. Landscape Capital Management L.L.C. purchased a new stake in Dyadic International during the 3rd quarter worth about $190,000. Geode Capital Management LLC lifted its holdings in Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after buying an additional 36,266 shares during the last quarter. Finally, Truist Financial Corp boosted its position in shares of Dyadic International by 30.5% during the 3rd quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock worth $385,000 after acquiring an additional 76,200 shares in the last quarter. 27.95% of the stock is currently owned by institutional investors and hedge funds.

Dyadic International Trading Down 3.2%

Dyadic International stock traded down $0.02 during midday trading on Friday, reaching $0.68. 207,216 shares of the stock traded hands, compared to its average volume of 111,080. The firm has a market cap of $24.73 million, a PE ratio of -2.71 and a beta of 1.29. The company has a current ratio of 2.68, a quick ratio of 2.85 and a debt-to-equity ratio of 4.08. The company has a 50-day simple moving average of $0.83 and a two-hundred day simple moving average of $0.94. Dyadic International has a 12-month low of $0.65 and a 12-month high of $1.43.

Dyadic International (NASDAQ:DYAI) last issued its quarterly earnings results on Wednesday, March 25th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.03). The business had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $1.34 million. Dyadic International had a negative return on equity of 695.96% and a negative net margin of 239.67%. Research analysts expect that Dyadic International will post -0.18 earnings per share for the current fiscal year.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.